Psoriasis drug shows promise in preventing deadly transplant complication
NCT ID NCT04112810
Summary
This study tested whether tildrakizumab, a drug approved for psoriasis, could prevent graft-versus-host disease (GVHD) in patients receiving stem cell transplants for blood cancers. The trial involved 51 adults who received the drug alongside their transplant to see if it could reduce GVHD without increasing cancer relapse. Researchers measured whether patients remained free from severe GVHD, cancer return, or death for one year after transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.